Comparable to Form PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Application Number	10/041,556
Filing Date	January 10, 2002
First Named Inventor	Wilfried Lubisch
Group Art Unit	1624
Examiner Name	COLEMAN
Attorney Docket No.	ABB10010P0690US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
BC		WO 01/16136 A2	March 8, 2001	Agouron Pharmaceuticals, Inc. Cancer Research Campaign Technology Limited		
** BC		WO 01/23390 A2	April 5, 2001	BASF Aktiengesellschaft		

Examiner Signature	Brenda Coleman	Date Considered	June 29, 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. [6] Applicant is to place a checkmark here if English language Translation is attached.

** structures only

Comparable to Form PTO/SB/08A (08-03
Approved for use through 07/31/2006 OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/041,556
Filing Date	January 10, 2002
First Named Inventor	Wilfried Lubisch
Group Art Unit	1624
Examiner Name	COLEMAN
Sheet 3 of 4	Attorney Docket No. ABB10010P0690US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BC		BURKART, et al., Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozcin; March 1999, pp. 314-319; Vol. 5, No. 3, Nature Medicine	
BC		CHEN, et al., Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide; (1998), pp. 303-307; Vol. 22, Cancer Chemotherapy and Pharmacology.	
BC		EHRLICH, et al., Inhibition of the induction of collagenase by interleukin 1ß in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobensamide; March 1995, pp. 171-172; Vol. 15; Rheumatol Int.	
BC		GÄKEN, et al., Efficient Retroviral Infection of Mammalian Cells Is Blocked by Inhibition of Poly (ADP-Ribose) Polymerase Activity; June 1996; pp. 3992-4000; Vol. 70, No. 6; Journal of Virology	
BC		CUZZOCREA, et al., Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occulosion and reperfusion; 1997; pp. 1065-1074; Vol. 121; British Journal of Pharmacology	
BC		CUZZOCREA, et al., Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation; 1998, pp. 67-76; Vol. 342; European Journal of Pharmacology	
BC		IKAI, et al., Immunohistochemical Demonstration of Poly (Adenosine Diphosphate-Ribose) Synthetase in Bovine Tissues; 1983; pp. 1261-1264; Vol. 31, No. 11; The Hournal of Histochemistry and Cytochemistry	
BC		KRÖGER, et al., Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice; 1996; pp. 203-215;Vol. 20, No. 2; Inflammation	
BC		SHALL, SYDNEY; ADP-Ribose in DNA Repair; A New Component of DNA Excision Repair; 1984; pp. 1-65; Vol. II, Advances in Radiation Biology	
BC		KAMEOKA, et al., Poly (ADP-ribose) Polymerase Is Involved in PMA-induced Activation of HIV-1 in U1 Cells by Modulating the LTR Function; 1999; pp. 285-289; Vol. 262; Biochemical and Biophysical Research Communications	
BC		SATOH, et al., Role of poly(ADP-ribose) formation of DNA repair; March 1992; pp. 356-358; Vol. 356; Nature	
BC		SZABÓ, et al., Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase; March 1998; 3867-3872; Vol. 95; Proc. Natl. Acad. Sci. USA	
BC		WELTIN, et al., Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly (ADP-Ribose) Polymerase Inhibitor; 1995; pp. 265-271, Vol. 17, No. 4; Int. J. Immunopharmac	

BC		THIEMERMANN, et al., Inhibition of the activity of poly (ADP ribose) synthetase reduces ischemia -reperfusion injury in the heart and skeletal muscle; January 1997; pp. 679-683; Vol. 94; Proc. Natl. Acad. Sci. USA	
Examiner Signature	Brenda Coleman	Date Considered	June 29, 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**